

# Anti-CCP ELISA



## 류마티즘 조기 진단 !!!



- High Sensitivity (73%) & High Specificity (98.5%)
- False positive 결과 최소화
- Wide Range: 5 ~ 200 RU/ ml
- 연 2회 NEQAS 정도관리 검사 실시



### 민감도 및 특이도 비교

Company	Target antigen	Specificity (n=202)	Sensitivity @98% specificity
<b>EUROIMMUN</b>	<b>CCP</b>	<b>98.5%</b>	<b>73%</b>
Phadia	CCP	98.5%	74%
<b>Axis-Shield</b>	<b>CCP</b>	<b>97%</b>	<b>70%</b>
Eurodiagnostica	CCP	97%	73%
Inova 2. Generation	CCP	97%	64%
Inova 3. Generation	CCP	96%	67%
<b>Inova 3.1. Generation</b>	<b>CCP</b>	<b>64.9%</b>	<b>67%</b>
Genesis	Citrullinate Filaggrin	94.6%	41%
Orgentec	MCV	93.1%	62%
Astra	Citrullinate EBV-Peptid	92.6%	47%
Rheumafactor-Test	IgG	86.1%	17%
Aesku	Citrullinate IgG	53%	44%

### 다양한 질환 그룹에서 False positive results

Company	Connective Tissue Disease (39)	Other Rheumatic Disease (12)	Autoimmune thyroid Disease (15)	Viral Infection (39)	Lyme Disease (6)	Neoplasia (17)	Healthy blood donor (39)	Total (202)
<b>EUROIMMUN</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>3</b>
Phadia	0	0	0	2	0	1	0	3
<b>Axis-Shield</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>1</b>	<b>2</b>	<b>6</b>
Eurodiagnostica	4	0	1	0	1	0	0	6
Inova 2	1	1	0	2	0	0	2	6
Inova 3	5	1	0	1	0	0	1	8
<b>Inova 3.1</b>	<b>7</b>	<b>7</b>	<b>5</b>	<b>22</b>	<b>0</b>	<b>15</b>	<b>15</b>	<b>71</b>
Genesis	1	0	0	6	1	0	3	11
Orgentec	4	0	0	10	0	0	0	14
Astra	2	0	2	5	0	2	4	15
Rheumafactor-Test	16	1	0	8	0	2	1	28
Aesku	22	8	5	25	2	6	27	95

Bizzarro et al. 5th International Congress on Autoimmunity, Sorrent, Italien, 2006

"A comparative evaluation of 11 second and third generation ELISA methods for the detection of antibodies to citrullinated"